Osteoporosis: A Clinical Review
Definition
Osteoporosis is a systemic skeletal disorder characterized by compromised bone strength, which predisposes an individual to an increased risk of fracture (1). This definition encompasses two distinct but interconnected components. The first is bone density, which is the measurable quantity of bone mineral per unit area (g/cm²). The second, more complex component is bone quality, a qualitative term describing the integrity of the bone's microarchitecture (the size, shape, and connectivity of the trabecular struts), the rate of bone turnover, the extent of accumulated microdamage, and the quality of collagen and mineralization (1). A patient can have a relatively preserved bone density but poor bone quality, which still results in a fragile skeleton.
Operationally, for pragmatic clinical use, the World Health Organization (WHO) defines osteoporosis based on a Bone Mineral Density (BMD) measurement using a T-score. The T-score represents the number of standard deviations a patient's BMD is from the mean BMD of a healthy, young-adult reference population (13):
Normal: T-score ≥ -1.0
Osteopenia (Low Bone Mass): T-score between -1.0 and -2.5. This is not a disease but a risk factor, indicating that bone density is lower than average.
Osteoporosis: T-score ≤ -2.5. This is the densitometric diagnosis of the disease.
Crucially, modern clinical practice emphasizes that a fragility fracture—a fracture resulting from a fall from standing height or less—constitutes a clinical diagnosis of osteoporosis, irrespective of the T-score (5). A patient who has sustained such a fracture has unequivocally demonstrated that their skeletal strength is insufficient for normal physiological loads. This principle is paramount in the Malaysian context, as it empowers clinicians to initiate treatment for high-risk individuals without waiting for a DXA scan, which may be subject to delays or limited access in certain regions.
Epidemiology
Globally, osteoporosis has reached pandemic proportions, affecting an estimated 200 million individuals, with a fragility fracture occurring approximately every three seconds (17). While historically perceived as a disease of Caucasian populations in Western countries, the demographic epicenter is shifting dramatically. By 2050, it is projected that over half of all hip fractures worldwide will occur in Asia, driven by increasing life expectancy and urbanization (7).
In Malaysia, the burden is escalating at an alarming rate. The nation is aging rapidly, and this demographic shift is the primary driver for a projected 3.55-fold increase in hip fractures, from an estimated 5,880 cases in 2018 to a staggering 20,893 cases by 2050 (2). This represents a looming public health crisis.
Prevalence: A landmark Malaysian study highlighted the scale of the problem, finding the prevalence of osteoporosis to be 24.1% among postmenopausal women (27). The prevalence of osteopenia, the precursor state, is even higher, affecting a majority of older adults and creating a vast reservoir of future fracture risk (29).
Demographics: The disease disproportionately affects women due to the precipitous loss of bone-protective estrogen after menopause. Furthermore, multiple local studies have consistently identified that ethnic Chinese have the highest prevalence of osteoporosis and the highest incidence of hip fractures when compared to ethnic Malays and Indians (27). The reasons for this are likely multifactorial, involving a combination of genetic predisposition, dietary habits, and potentially lower average body weight.
Socioeconomic Impact: Osteoporosis is not just a biological disease; it is shaped by social determinants. Studies in Malaysia have shown that lower monthly income and lower levels of formal education are significant independent predictors of osteoporosis (4). The economic consequences are profound, encompassing not only the direct costs of hospitalization and surgery but also the immense indirect costs related to long-term care, loss of patient productivity, and the burden on family caregivers.
Etiology
The development of osteoporosis is multifactorial, stemming from primary factors related to aging and genetics, or secondary to a wide array of medical conditions and medications. A meticulous risk factor assessment is the cornerstone of identifying patients for further investigation.
Primary Osteoporosis Risk Factors
Non-Modifiable:
Advancing Age: The single most powerful, non-modifiable risk factor. Bone mass naturally declines with age, while bone quality deteriorates, leading to an exponential increase in fracture risk (16).
Female Gender and Post-menopause: Women typically achieve a lower peak bone mass than men and then experience a period of accelerated bone loss after menopause (16).
Ethnicity: Asian and Caucasian populations are at the highest risk (16).
Parental History of Hip Fracture: This is a strong, independent risk factor, reflecting a significant genetic contribution to bone strength and fracture susceptibility (16).
Previous Fragility Fracture: This is the single strongest predictor of a future fracture. A prior fracture more than doubles the risk of a subsequent fracture, a phenomenon known as the "fracture cascade." The first fracture is a sentinel event that must trigger intervention (32).
Modifiable:
Low Body Weight (BMI < 19 kg/m²): A major risk factor due to less mechanical loading on the skeleton and reduced peripheral conversion of androgens to estrogen in adipose tissue (16).
Nutritional Deficiencies: Inadequate intake of calcium and Vitamin D is critical. Vitamin D deficiency is highly prevalent in Malaysia, a phenomenon termed the "Malaysian Vitamin D Paradox." Despite abundant sunshine, factors like sun avoidance, cultural attire, and urbanization contribute to insufficient UVB exposure, impairing Vitamin D synthesis (7).
Sedentary Lifestyle: Lack of weight-bearing and muscle-strengthening exercise results in lower peak bone mass and accelerates age-related bone loss (16).
Smoking and Excessive Alcohol Intake: Smoking is directly toxic to osteoblasts, while excessive alcohol intake interferes with calcium absorption and hormonal regulation (13, 16).
Secondary Osteoporosis
This form arises from specific medical conditions or medications. It is crucial to investigate for these, especially in men, pre-menopausal women, or those with unusually severe or early-onset bone loss.
Endocrine Disorders: Hyperthyroidism, primary hyperparathyroidism, Cushing's syndrome, and hypogonadism (in both sexes) are classic causes (12).
Gastrointestinal Conditions: Malabsorption syndromes like celiac disease or inflammatory bowel disease impair the absorption of calcium and vitamin D (12).
Rheumatologic Conditions: Chronic inflammatory states like rheumatoid arthritis accelerate bone loss through inflammatory cytokines and the frequent use of glucocorticoids (12).
Drug-Induced: Long-term glucocorticoid use (e.g., oral prednisolone >5mg/day for >3 months) is the most common and devastating iatrogenic cause (14). Other important culprits include long-term use of proton pump inhibitors (PPIs), which may reduce calcium absorption, and certain anti-epileptic drugs (14).
Pathophysiology
Osteoporosis is an active disease process driven by a fundamental imbalance in bone remodeling. This lifelong process, occurring in millions of microscopic Bone Remodeling Units (BRUs), involves the removal of old bone by osteoclasts (resorption) and the deposition of new bone by osteoblasts (formation). In healthy adults, this process is tightly coupled, with resorption matching formation. In osteoporosis, bone resorption chronically exceeds bone formation, leading to a net loss of bone mass, perforation of the trabecular architecture, and a marked increase in skeletal fragility (1).
The master regulatory pathway governing this balance is the RANK/RANKL/OPG system:
RANKL (Receptor Activator of Nuclear Factor-κB Ligand) is the primary "go" signal for osteoclast formation and activation. It can be thought of as the accelerator for bone resorption.
OPG (Osteoprotegerin) is a soluble decoy receptor that acts as the "brake." It binds to RANKL, preventing it from activating osteoclasts and thus inhibiting bone resorption.
The ratio of RANKL to OPG is the ultimate determinant of bone resorption. In post-menopausal osteoporosis, the loss of estrogen causes a dramatic upregulation of RANKL and a downregulation of OPG. This shifts the balance heavily in favor of RANKL, leading to excessive osteoclast activity and a period of accelerated bone loss (1). Similarly, inflammatory cytokines and glucocorticoids also exert their damaging effects by increasing the RANKL/OPG ratio.
Clinical Presentation
Osteoporosis is famously known as a "silent disease" because it is entirely asymptomatic until a fracture occurs (7). It does not cause bone pain, joint aches, or any other symptoms in the absence of a fracture. This insidious nature underscores why proactive risk assessment and screening are paramount.
Presentation with a Fragility Fracture
The first clinical manifestation of osteoporosis is typically a fracture from minimal trauma. This is the sentinel event that unmasks the underlying disease.
Diagnostic Clue: Any low-trauma fracture in an adult over 50 years of age must be considered an osteoporotic fragility fracture until proven otherwise.
Common Fracture Sites and Their Presentation:
Vertebral Compression Fractures: These are the most common osteoporotic fractures, but up to two-thirds can be clinically silent. When symptomatic, they present with sudden, sharp, localized back pain.
⚠️ Red Flag Signs & Symptoms: The cumulative effect of multiple vertebral fractures leads to classic postural changes: progressive height loss (>4 cm from peak height) and the development of a smooth, thoracic kyphosis (often called a "dowager's hump"). These are not signs of "old age" but are signs of established, severe osteoporosis with multiple fractures (13).
Hip Fractures: These are the most devastating and life-altering fractures. Patients typically present after a fall with severe pain in the groin or anterior thigh, an absolute inability to bear weight, and a characteristically shortened and externally rotated leg on examination (33).
Distal Radius (Colles') Fractures: These are very common in the early post-menopausal years and are often the first sentinel fracture a woman sustains. They typically result from a fall on an outstretched hand (FOOSH) (13).
Complications
The primary complications of osteoporosis are the fractures themselves and their severe, cascading consequences:
Chronic Pain and Deformity: Particularly from multiple vertebral fractures, leading to debilitating back pain and a pronounced kyphotic deformity. This can, in turn, lead to restrictive lung disease and gastrointestinal issues like early satiety due to compression of the abdominal cavity.
Profound Loss of Independence: Following a hip fracture, most patients fail to regain their pre-fracture level of mobility and function. Over 40% will require a walking aid permanently, and many will lose the ability to perform basic activities of daily living (7).
Reduced Quality of Life: This stems from a combination of chronic pain, physical disability, and a significant psychological burden, including fear of falling, social isolation, and depression.
Increased Mortality: Hip fractures are associated with a shocking 20% mortality rate within the first year in the Malaysian context (7). Death is often not from the fracture itself but from the complications of prolonged immobility, such as pneumonia, pulmonary embolism, and sepsis.
Prognosis
The prognosis after a major osteoporotic fracture is guarded and is heavily influenced by the patient's age, number of comorbidities, and pre-fracture functional status. As noted, one-year mortality after a hip fracture is approximately 20% (7). For survivors, the loss of function is profound, with fewer than one in four Malaysian patients regaining full mobility within six months (7). The presence of a previous fragility fracture is the strongest predictor of future fractures, making aggressive secondary prevention not just beneficial, but essential to alter the patient's prognosis (32).
Differential Diagnosis
The diagnosis of primary osteoporosis is established by meeting specific densitometric (T-score ≤ -2.5) or clinical (fragility fracture) criteria. Therefore, the main "differential" process is not to distinguish it from other diseases that cause fractures, but rather to diligently exclude secondary causes of bone loss. For every new diagnosis of osteoporosis, a workup to rule out key mimics and contributors is mandatory. Important considerations include:
Osteomalacia: Characterized by defective bone mineralization, often due to severe Vitamin D deficiency. It can be distinguished by low or normal serum calcium, low serum phosphate, and markedly elevated alkaline phosphatase and parathyroid hormone levels.
Multiple Myeloma: A malignancy of plasma cells that can cause lytic bone lesions. It should be suspected in patients with bone pain, anemia, renal impairment, and hypercalcemia. A high ESR and serum protein electrophoresis are key investigations.
Metastatic Bone Disease: Cancers, particularly of the breast, prostate, lung, kidney, and thyroid, can metastasize to bone. These lesions are often associated with more severe, constant pain that is present even at rest.
Investigations
The diagnostic pathway is a systematic process of risk assessment, definitive imaging, and laboratory testing to exclude other pathologies.
Immediate & Bedside Tests
Clinical Risk Assessment Tools: These are the critical first step to stratify patients and rationalize the use of resources.
FRAX® (Fracture Risk Assessment Tool): This is the CPG-recommended tool to calculate an individual's 10-year probability of a hip fracture and a major osteoporotic fracture. For the Malaysian population, the Singapore algorithm should be used. This tool is invaluable for guiding treatment decisions in patients with osteopenia, with specific intervention thresholds (≥3% for hip fracture or ≥20% for major osteoporotic fracture) (10).
OSTA (Osteoporosis Self-Assessment Tool for Asians): A simpler, validated screening tool that uses only age and body weight. It is highly effective in primary care to identify high-risk post-menopausal women who should be prioritized for a definitive DXA scan (10).
Diagnostic Workup
First-Line & Gold Standard Investigation: Dual-Energy X-ray Absorptiometry (DXA) is the definitive test to measure BMD at the most clinically relevant sites: the hip and lumbar spine. It is a precise, low-radiation technique used for initial diagnosis, establishing a pre-treatment baseline, and for monitoring the response to therapy (4).
Plain Radiographs (X-rays): While insensitive for detecting early bone loss, X-rays are essential for confirming the presence of fractures, especially asymptomatic or minimally symptomatic vertebral fractures, which may appear as wedge deformities or crush fractures.
Monitoring & Staging (Excluding Secondary Causes)
A baseline panel of blood tests is mandatory before initiating any long-term osteoporosis therapy to rule out common secondary causes.
Full Blood Count (FBC): To screen for anemia (suggesting malabsorption) or abnormal cell lines (suggesting myeloma).
Renal Profile (Urea, Creatinine, eGFR): This is absolutely essential, as many bisphosphonates are contraindicated in severe renal impairment (e.g., eGFR < 35 mL/min). It also screens for chronic kidney disease-mineral and bone disorder (CKD-MBD) (17).
Serum Calcium (Corrected), Phosphate, and Alkaline Phosphatase (ALP): To assess for metabolic bone diseases. Hypocalcemia is a contraindication to starting bisphosphonate or denosumab therapy and must be corrected first (17).
Thyroid Function Tests (TSH): To rule out hyperthyroidism, a common and easily treatable cause of secondary osteoporosis (17).
Serum 25-hydroxyvitamin D (25(OH)D): To assess for Vitamin D deficiency, which is highly prevalent in Malaysia and requires aggressive correction to ensure the efficacy of any osteoporosis treatment (41).
Serum Testosterone (in men): To screen for hypogonadism, a major and treatable cause of osteoporosis in men (33).
Management
Management goals are to prevent fractures, stabilize or increase bone mass, and maintain the patient's function, independence, and quality of life.
Management Principles
The management of osteoporosis is a long-term commitment that combines universal non-pharmacological interventions with risk-stratified pharmacological therapy. The primary goal is to treat a patient's absolute fracture risk, not just a T-score on a DXA report.
Acute Stabilisation (The First Hour)
In the context of an acute fracture, particularly a hip fracture, management follows standard ATLS principles with a focus on pain control and hemodynamic stability.
Circulation: Secure two large-bore IV cannulas, provide adequate analgesia (often requiring an opioid or a regional nerve block), and assess for any signs of shock.
Definitive management requires prompt orthopedic consultation for surgical fixation, ideally within 48 hours of presentation. Early surgery is proven to reduce pain, allow for earlier mobilization, and significantly decrease the high rates of medical complications and mortality associated with prolonged immobility (10).
Definitive Therapy
First-Line Treatment: Non-Pharmacological
These interventions are the absolute foundation of care for every patient with osteoporosis or at high risk of developing it.
Calcium and Vitamin D: Ensure adequate intake, as this is a prerequisite for any pharmacological therapy to be effective.
Calcium: 1000-1200 mg/day, preferably from diet (e.g., high-calcium milk, anchovies/ikan bilis, tofu, tempeh, leafy greens like sawi). Supplements should be used to bridge any dietary gap (10).
Vitamin D: 800 IU/day. Given the high prevalence of deficiency in Malaysia, supplementation is almost always necessary (10).
Exercise: A comprehensive program is crucial. This must include weight-bearing exercise (brisk walking, jogging, dancing for 30-40 minutes, 3-5 times per week) to stimulate bone and resistance/muscle-strengthening exercise to improve muscle mass, strength, and balance (17).
Fall Prevention: This is a critical, high-yield intervention. A multifactorial assessment should be conducted, including a medication review to reduce psychoactive drugs, vision correction, and a detailed home safety assessment to remove tripping hazards like rugs and clutter and to improve lighting (9).
Second-Line/Escalation: Pharmacological Therapy
The choice of drug is based on the patient's absolute fracture risk category, as outlined in the 2022 Malaysian CPG update (42).
High-Risk Patients (T-score ≤ -2.5 or osteopenia with a high FRAX score):
First-Line: Oral bisphosphonates (e.g., Alendronate 70 mg once weekly). These are effective and cost-efficient. Patients must be counseled carefully on administration (take with a full glass of plain water on an empty stomach and remain upright for 30-60 minutes) to prevent esophagitis (40).
Alternatives: IV bisphosphonates (e.g., Zoledronic acid 5 mg once yearly) are an excellent option for patients with gastrointestinal intolerance to oral agents or with adherence concerns. Denosumab is another potent anti-resorptive alternative (40).
Very High-Risk Patients (Recent major fracture, fractures while on therapy, multiple fractures, or extremely low T-scores < -3.0):
First-Line: Anabolic agents should be considered to rapidly build new bone and reduce imminent fracture risk.
Teriparatide (a PTH analogue given as a daily subcutaneous injection) (40).
Romosozumab (a sclerostin inhibitor given as a monthly subcutaneous injection). It has a powerful dual effect of increasing bone formation and decreasing resorption but is contraindicated in patients with a recent history of myocardial infarction or stroke (40).
Crucially, a course of anabolic therapy (typically 1-2 years) must be immediately followed by an anti-resorptive agent (like a bisphosphonate or denosumab) to consolidate and maintain the gains in bone density (40).
Supportive & Symptomatic Care
This involves adequate analgesia for acute fractures, ongoing nutritional support, and a structured rehabilitation program with physiotherapy and occupational therapy to restore function, improve gait and balance, and build patient confidence.
Key Nursing & Monitoring Instructions
Emphasize strict adherence to medication schedules and correct administration procedures.
Monitor for and educate patients on potential side effects (e.g., GI upset for oral bisphosphonates; flu-like acute phase reaction for IV zoledronic acid).
Counsel on the rare but serious side effects of long-term therapy, such as osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF), and the importance of good dental hygiene.
Monitor treatment response with a repeat DXA scan 1-2 years after initiating therapy, with the goal of stabilizing or significantly increasing BMD (16).
Long-Term Plan & Patient Education
Duration of Therapy: For patients on oral bisphosphonates, treatment efficacy and safety should be formally re-evaluated after 5 years (3 years for IV zoledronic acid). In patients who have responded well and are now at a lower risk, a "drug holiday" of 1-2 years may be considered. This is strictly contraindicated for denosumab, as its cessation leads to a rapid reversal of BMD gains and a well-documented rebound increase in the risk of multiple vertebral fractures (16, 40).
Secondary Prevention: The most critical intervention in the long-term plan is closing the post-fracture care gap. The Fracture Liaison Service (FLS) is the internationally recognized gold-standard model of care. An FLS coordinator systematically identifies every patient with a fragility fracture, ensuring they are investigated for osteoporosis and initiated on appropriate therapy, thereby preventing the next fracture (5).
When to Escalate
A house officer plays a pivotal role in ensuring every patient with a fragility fracture is managed holistically for their underlying osteoporosis.
Call Your Senior (MO/Specialist) if:
A patient presents with a fragility fracture. This should be recognized not just as an orthopedic injury but as a medical emergency requiring a comprehensive, multidisciplinary long-term management plan.
Baseline investigations reveal significant abnormalities that may contraindicate or complicate first-line therapies (e.g., hypercalcemia, severe renal impairment, suspected malignancy).
The patient has contraindications to first-line therapies or is considered to be at very high risk, requiring consideration for anabolic agents.
Referral Criteria:
Orthopedics: For the acute surgical management of all fractures.
Endocrinology/Rheumatology: For complex cases, management of secondary causes, interpretation of ambiguous results, or initiation of anabolic agents.
Physiotherapy/Occupational Therapy: For all patients, to create a personalized rehabilitation and fall prevention program.
Fracture Liaison Service (FLS): If available, every single fragility fracture patient must be referred to the FLS for systematic and evidence-based secondary prevention.
References
Cianferotti, L., & Brandi, M. L. (2020). Osteoporosis: Pathophysiology and therapeutic options. International Journal of Molecular Sciences, 21(15), 5243. https://pmc.ncbi.nlm.nih.gov/articles/PMC7415937/
Ministry of Health Malaysia. (2022). Management of Osteoporosis (3rd Edition). https://www.moh.gov.my/moh/resources/Penerbitan/CPG/Rheumatology/221115_MOS_CPG-Management_of_Osteoporosis-ed3_PREVIEW.pdf
Ministry of Health Malaysia. (2012). Clinical Practice Guidelines: Management of Osteoporosis. https://www.osteoporosis.my/GUI/pdf/CPG2012.pdf
Shuid, A. N., Siang, T. K., Abdullah, S., Muhammad, N., Mohamed, N., & Soelaiman, I. N. (2020). Development of Osteoporosis Screening Algorithm for Population Aged 50 Years and above in Klang Valley, Malaysia. International Journal of Environmental Research and Public Health, 17(7), 2526. https://www.mdpi.com/1660-4601/17/7/2526
Fragility Fracture Network of Malaysia. (n.d.). Fracture Liaison Service (FLS) Framework. https://fragilityfracturenetwork.org/wp-content/uploads/2023/10/220609_ffnm_fls-framework_v3-1.pdf
Asia Pacific Fragility Fracture Alliance. (n.d.). Current & future challenges of hip fracture management in Malaysia. https://apfracturealliance.org/current-future-challenges-of-hip-fracture-management-in-malaysia/
Ratnasingam, J. (2021). Osteoporosis: A Silent Epidemic Affecting Malaysian Women. Galen Centre for Health & Social Policy. https://ova.galencentre.org/osteoporosis-a-silent-epidemic-affecting-malaysian-women-dr-jeyakantha-ratnasingam/
Shuid, A. N., et al. (2020). The Current and Future Challenges of Hip Fracture Management in Malaysia. Malaysian Orthopaedic Journal, 14(3), 1-8. https://www.researchgate.net/publication/347589571_The_Current_and_Future_Challenges_of_Hip_Fracture_Management_in_Malaysia
CodeBlue. (2021). Bone Health Alliance Malaysia Fights Osteoporosis. https://codeblue.galencentre.org/2021/01/bone-health-malaysia-fights-osteoporosis/
Ministry of Health Malaysia. (2015). Clinical Practice Guidelines: Management of Osteoporosis (Second Edition). https://www.moh.gov.my/moh/resources/Penerbitan/CPG/Rheumatology/CPG%20Mx%20of%20Osteoporosis%20Second%20Edition%20(2015).pdf
American Medical Association. (n.d.). What doctors wish patients knew about osteoporosis. https://www.ama-assn.org/delivering-care/public-health/what-doctors-wish-patients-knew-about-osteoporosis
Patient.info. (n.d.). Fragility Fractures: Causes, Symptoms, Treatment. https://patient.info/doctor/fragility-fractures
Elder.org. (n.d.). What is the osteoporosis T-score? https://www.elder.org/care-guides/what-is-the-t-score/
Medical News Today. (n.d.). What T-score value indicates osteoporosis? https://www.medicalnewstoday.com/articles/t-score-osteoporosis
Johns Hopkins Medicine. (n.d.). Bone Densitometry. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/bone-densitometry
Lim, P. S. (2018). Management of postmenopausal osteoporosis. Malaysian Family Physician, 13(1), 35-43. https://e-mfp.org/wp-content/uploads/2018/06/management-of-postmenopausal-osteoporosis.pdf
Myanmar Endocrine Society. (2019). Myanmar Clinical Practice Guideline for Osteoporosis. Journal of the ASEAN Federation of Endocrine Societies, 34(Suppl 1), 1-30. https://www.asean-endocrinejournal.org/index.php/JAFES/article/view/29/439
University of Alabama at Birmingham. (n.d.). T-Scores. https://www.uab.edu/shp/toneyourbones/step-2-bone-density-testing/the-results-of-your-scan/t-scores
Morin, S. N., et al. (2023). Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. CMAJ, 195(39), E1333-E1352. https://www.cmaj.ca/content/195/39/E1333
Che-Seman, Z., et al. (2019). A summary of the Malaysian Clinical Guidance on the management of postmenopausal and male osteoporosis, 2015. Malaysian Family Physician, 14(1), 38-46. https://pmc.ncbi.nlm.nih.gov/articles/PMC6372736/
International Osteoporosis Foundation. (n.d.). Fragility fractures. https://www.osteoporosis.foundation/health-professionals/fragility-fractures
Ramli, A., et al. (2022). Screening and management of osteoporosis: a survey of knowledge, attitude and practice among primary care physicians in Malaysia. BMC Primary Care, 23(1), 86. https://pmc.ncbi.nlm.nih.gov/articles/PMC9041673/
International Osteoporosis Foundation. (n.d.). Pathophysiology. https://www.osteoporosis.foundation/health-professionals/about-osteoporosis/pathophysiology
Florencio-Silva, R., et al. (2015). Biology of Bone Remodeling. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK499863/
Li, Y., et al. (2024). Beyond Bone Loss: A Biology Perspective on Osteoporosis Pathogenesis, Multi-Omics Approaches, and Interconnected Mechanisms. Biomolecules, 14(6), 1443. https://www.mdpi.com/2227-9059/13/6/1443
Wu, Y., et al. (2023). The effect of cytokines on osteoblasts and osteoclasts in bone remodeling in osteoporosis: a review. Frontiers in Immunology, 14, 1222129. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1222129/full
Lee, J. K., et al. (2019). Prevalence and Predictors of Osteoporosis Among the Chinese Population in Klang Valley, Malaysia. Applied Sciences, 9(9), 1820. https://www.mdpi.com/2076-3417/9/9/1820
International Journal of Women's Health and Reproduction Sciences. (2020). [Relevant Article]. https://www.ijwhr.net/pdf/pdf_IJWHR_418.pdf
Chin, K. Y., et al. (2020). Determinants of Bone Health Status in a Multi-Ethnic Population in Klang Valley, Malaysia. International Journal of Environmental Research and Public Health, 17(4), 1164. https://pmc.ncbi.nlm.nih.gov/articles/PMC7014230/
Tan, M. W., et al. (2019). Osteoporosis care gap following fragility fracture in a tertiary teaching hospital. Acquaintance Journal of Medical Sciences. https://acquaintpublications.com/article/osteoporosis_care_gap_following_fragility_fracture_in_a_tertiary_teaching_hospital
Malaysiakini. (2023). BHAM Champions Active Aging for Better Bone Health. https://m.malaysiakini.com/announcement/723043
European Federation of National Associations of Orthopaedics and Traumatology. (n.d.). Osteoporosis and Fragility Fractures. In The EFORT White Book. https://www.ncbi.nlm.nih.gov/books/NBK585962/
Medscape. (n.d.). Osteoporosis Clinical Presentation. https://emedicine.medscape.com/article/330598-clinical
Cleveland Clinic. (n.d.). Osteoporosis: Symptoms, Causes and Treatment. https://my.clevelandclinic.org/health/diseases/4443-osteoporosis
Che-Seman, Z., et al. (2019). An update of the Malaysian Clinical Guidance on the management of glucocorticoid-induced osteoporosis, 2015. Malaysian Family Physician, 14(1), 47-53. https://pmc.ncbi.nlm.nih.gov/articles/PMC6372780/
Maedica. (2022). Screening and Diagnosing Osteoporosis Among Postmenopausal Women. https://www.maedica.ro/articles/2022/2/2022_17(20)_No2_pg492-504.pdf
Rahim, N. A. A., et al. (2022). Screening and Diagnosing Osteoporosis Among Postmenopausal Women in Primary Care Settings in Malaysia: A Systematic Review. Medicina, 58(8), 1081. https://pmc.ncbi.nlm.nih.gov/articles/PMC9375864/
Health Tourism. (n.d.). Bone Density Test in Malaysia. https://www.health-tourism.com/bone-density-test/malaysia/
National Health Service (NHS). (n.d.). Bone density scan (DEXA scan). https://www.nhs.uk/conditions/dexa-scan/
Hospital Canselor Tuanku Muhriz UKM. (2023). Osteoporosis and Osteoporotic Agents in HCTM. https://hctm.ukm.my/farmasi/wp-content/uploads/2023/10/Edisi-23-Isu-5-Osteoporosis-and-Osteoporotic-Agents-in-HCTM.pdf
WebMD. (n.d.). Know Your Osteoporosis Blood Test Markers. https://www.webmd.com/osteoporosis/features/know-your-osteoporosis-blood-test-markers
Lim, P. S., et al. (2023). A summary of the Malaysian Clinical Practice Guidelines on the management of postmenopausal osteoporosis, 2022. Malaysian Family Physician, 18(2), 1-8. https://pubmed.ncbi.nlm.nih.gov/37496985/
Hospital Segamat. (2013). Bulletin Pharmacy. https://jknjohor.moh.gov.my/hsegamat/uploads/penerbitan/buletin/buletin_pharmacyv2_2013.pdf
Asia Pacific Fragility Fracture Alliance. (n.d.). Formation of Malaysian, multi-stakeholder alliance. https://apfracturealliance.org/formation-of-malaysian-multi-stakeholder-alliance-striving-to-curb-brittle-bones/
